In this view, it will be interesting to evaluate whether MYC‐driven tumours, which are known to be particularly susceptible to spliceosome inhibition [103], are also particularly sensitive to the anti‐tumoral activity of CLK inhibitors and whether these drugs synergise in combined regimens. The gene discussed is CLK1; the disease is neoplasm.